Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Low-Risk MDS: What To Do?

46:39
 
Share
 

Manage episode 516126784 series 2892359
Content provided by Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping the future of low-risk MDS management, and offers a preview of high-risk MDS developments, including insights from the VERONA study.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

  continue reading

252 episodes

Artwork

Low-Risk MDS: What To Do?

Healthcare Unfiltered

15 subscribers

published

iconShare
 
Manage episode 516126784 series 2892359
Content provided by Chadi Nabhan. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Chadi Nabhan or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Returning guest Dr. Amer Zeidan of Yale Medicine and Smilow Cancer Hospital joins to discuss how clinicians should approach low-risk Myelodysplastic Syndrome (MDS), which is most often managed in community settings. He breaks down how to risk-stratify patients using molecular and prognostic markers, when to treat versus observe, and his preferred first-line therapies in today’s landscape. Dr. Zeidan also delves into the COMMANDS trial and the role of luspatercept, emerging questions shaping the future of low-risk MDS management, and offers a preview of high-risk MDS developments, including insights from the VERONA study.
Check out Chadi’s website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/
Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

  continue reading

252 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play